A

Aileron Therapeutics Inc
NASDAQ:RNTX

Watchlist Manager
Aileron Therapeutics Inc
NASDAQ:RNTX
Watchlist
Price: 1.35 USD -4.93% Market Closed
Market Cap: 35.5m USD

Intrinsic Value

The intrinsic value of one RNTX stock under the Base Case scenario is 0.52 USD. Compared to the current market price of 1.35 USD, Aileron Therapeutics Inc is Overvalued by 61%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RNTX Intrinsic Value
0.52 USD
Overvaluation 61%
Intrinsic Value
Price
A
Worst Case
Base Case
Best Case

Valuation History
Aileron Therapeutics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about RNTX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is RNTX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Aileron Therapeutics Inc.

Explain Valuation
Compare RNTX to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ALRN?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Aileron Therapeutics Inc

Current Assets 18.7m
Cash & Short-Term Investments 17.7m
Other Current Assets 1m
Non-Current Assets 85.5m
PP&E 1k
Intangibles 85.5m
Other Non-Current Assets 2k
Current Liabilities 5.7m
Accounts Payable 1.1m
Accrued Liabilities 4.6m
Non-Current Liabilities 3.3m
Other Non-Current Liabilities 3.3m
Efficiency

Free Cash Flow Analysis
Aileron Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Aileron Therapeutics Inc

Revenue
0 USD
Operating Expenses
-29.6m USD
Operating Income
-29.6m USD
Other Expenses
376k USD
Net Income
-29.2m USD
Fundamental Scores

RNTX Profitability Score
Profitability Due Diligence

Aileron Therapeutics Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROIC
ROIC is Increasing
ROE is Increasing
Low 3Y Average Gross Margin
47/100
Profitability
Score

Aileron Therapeutics Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

RNTX Solvency Score
Solvency Due Diligence

Aileron Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Short-Term Solvency
Low Altman Z-Score
59/100
Solvency
Score

Aileron Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RNTX Price Targets Summary
Aileron Therapeutics Inc

Wall Street analysts forecast RNTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RNTX is 8.16 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

Lowest
Price Target
6.06 USD
349% Upside
Average
Price Target
8.16 USD
504% Upside
Highest
Price Target
10.5 USD
678% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Aileron Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ALRN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ALRN Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one RNTX stock?

The intrinsic value of one RNTX stock under the Base Case scenario is 0.52 USD.

Is RNTX stock undervalued or overvalued?

Compared to the current market price of 1.35 USD, Aileron Therapeutics Inc is Overvalued by 61%.

Back to Top